Recently, a number of refinements in diagnostic modalities for detection of Borrelia burgdorferi infection have been developed. These include large-volume blood cultures, quantitative polymerase chain reaction (PCR) techniques, and 2-stage serologic testing. In the present study, we compared 6 diagnostic modalities in 47 adult patients who had a clinical diagnosis of erythema migrans. Quantitative PCR on skin biopsy-derived material was the most sensitive diagnostic method (80.9%), followed by 2-stage serologic testing of convalescent-phase samples (66.0%), conventional nested PCR (63.8%), skin culture (51.1%), blood culture (44.7%), and serologic testing of acute-phase samples (40.4%). Results of all assays were negative for 3 patients (6.4%). We conclude that the clinical diagnosis of erythema migrans is highly accurate in an area where B. burgdorferi is endemic if it is made by experienced health care personnel, but some patients with this diagnosis may not have B. burgdorferi infection. No single diagnostic modality is suitable for detection of B. burgdorferi in every patient with erythema migrans.
ythema migrans diagnosed in 1991 [2] , a number of refinements in laboratory-based diagnostic assays for this infection have occurred, including large-volume blood cultures to grow B. burgdorferi [3] ; 2-stage serologic testing, with interpretation of immunoblots by use of consensus criteria [4] ; and modifications of PCR amplification techniques to include nested and quantitative PCR [5, 6] . The purpose of the present study was to compare the sensitivity of various laboratory assays used at our center during the summer of 2000 for diagnosis of B. burgdorferi infection in adults with erythema migrans.
MATERIALS AND METHODS

Patient population.
All participants in this study were untreated adult patients with early Lyme disease associated with erythema migrans, and all were evaluated at one of Westchester Medical Center's Lyme Disease Diagnostic Centers (Valhalla and Hyde Park, New York) during the summer of 2000. All patients satisfied the Centers for Disease Control and Prevention's surveillance definition of Lyme disease [7] . All patients were prescribed antibiotics in accordance with recommended guidelines [8] .
Skin biopsy and culture. Skin biopsy specimens (diameter, 2 mm) were obtained from the advancing border of primary erythema migrans lesions, as described elsewhere [2] . Biopsy specimens were placed into transport medium, which consisted of incomplete Barbour-Stoenner-Kelly (BSK) medium (this preparation of BSK lacks rabbit serum and 35% bovine serum albumin [BSA] solution) plus rifampin, 40 mg/mL, for later laboratory processing. Tissue specimens were then transferred to a microtissue grinder (Spectrum Medical Industries), which contained 0.4 mL of incomplete BSK medium, and were ground; 0.2-0.3 mL of this suspension was added to a 7-mL screw-cap tube that contained 6 mL of complete BSK medium (with rabbit serum and 35% BSA solution, but devoid of antibiotics). The screw-cap tube was tightly capped and incubated at 33ЊC for the duration of culturing period. The remaining suspension plus the skin fragment itself were returned to the transport medium and sent for PCR studies. Cultures were examined by means of fluorescence microscopy at 2 weeks and, thereafter, at 2-week intervals for up to 8 weeks, as reported elsewhere [2] .
Blood culture. Six 3-mL samples of plasma (18 mL in total) were collected in EDTA-blood collection tubes from each patient by a single venipuncture. Plasma was separated after centrifugation of blood at 260g for 15 min. Within 3 h of the time of collection, six 3-mL aliquots of plasma were each inoculated into a 70-mL screw-cap plastic flask that contained 60 mL of antibiotic-free BSK medium, which was prepared as described elsewhere [3] . Cultures were incubated at 33ЊC for up to 12 weeks and examined as described above [2, 3] . PCR methods. DNA was extracted from the biopsy specimens and the associated transport medium by use of the IsoQuick nucleic acid isolation kit (Orca Research), as described elsewhere [9] . Purified DNA was resuspended in 50 mL of water.
A 353-bp region of the flagellin (flaB) gene of B. burgdorferi was amplified by use of a nested PCR protocol reported elsewhere by Barbour et al. [10] . Both first-and second-round PCR amplification were performed in a total volume of 25 mL that contained 100 mM (each) deoxynucleoside triphosphates, 1.25 U of Taq DNA polymerase (Roche Molecular Biochemicals), and 20 pmol of each primer in a "DNA engine" thermocycler (MJ Research). The template for the first-round reaction was 5 mL of resuspended specimen DNA, and 1 mL of the first-round reaction was used as the template for the second round of PCR. The thermal cycling profile for both rounds of PCR consisted of one 3-min cycle at 94ЊC, followed by 35 cycles of denaturation at 94ЊC for 30 s, annealing at 55ЊC for 30 s, and extension at 72ЊC for 30 s. To avoid cross-contamination and sample carryover, pre-and post-PCR sample processing and PCR amplification were performed in separate rooms, and plugged pipet tips were used for all fluid transfers. Amplified DNA products were detected by means of agarose gel electrophoresis in Tris-borate-EDTA buffer.
Quantitative PCR was accomplished by amplification of B. burgdorferi recA in a Lightcycler (Roche Molecular Biochemicals), as described elsewhere [6] . In brief, PCR was performed in a final volume of 10 mL that contained 1ϫ Lightcycler master mix (Roche), 3 mM MgCl 2 , 1 mM of each primer, and 2 mL of resuspended sample DNA. The recA-specific primers were nTM17.F and nTM17.R, as described elsewhere [11] . This primer set is B. burgdorferi-specific and resulted in single-copy detection sensitivity. The interassay variation of the quantitative PCR varied from 14% (110 copies per PCR reaction) to 56% (0.1-10 copies per PCR reaction), as determined by testing 30 (75%) of the 40 positive specimens in at least 2 different PCR runs. The amplification program consisted of heating at 95ЊC for 30 s, followed by 45 cycles of heating at 20ЊC/s to 95ЊC with a 1-s hold, cooling at 20ЊC/s to 60ЊC with 1-s hold, and heating at 20ЊC/s to 72ЊC with 10-s hold. The fluorescent product was collected at 80ЊC at the last step of each cycle, to minimize signal from nonspecific products. A 10-fold dilution series that contained 10-10 5 copies of the target gene was included in each PCR experiment and used to generate a standard curve for estimation of spirochete copy numbers in clinical specimens. In addition, samples that lacked template DNA were included as negative controls in each PCR run, to account for any contamination during the PCR procedure. A sample was considered positive only if it fulfilled both of the following 2 criteria: (1) it exhibited a log-linear (exponential) phase of amplification in the fluorescence curve, and (2) it showed a specific peak with a T m at 84ЊC in melting curve analysis and/ or a specific band with the expected molecular size on a 1.5% agarose gel by post-PCR analysis. An analysis of the number of B. burgdorferi detected in skin in relation to other clinical and laboratory test results will be provided in a separate paper.
Serologic testing. Acute-and convalescent-phase serum specimens were tested by use of a polyvalent (IgM/IgG) ELISA (Wampole Laboratories), performed in accordance with the manufacturer's instructions. Specimens that tested positive or equivocal using ELISA were then tested using commercially available IgM and IgG immunoblot assays (MarDX Diagnostics), according to the manufacturer's instructions (2-stage testing). For the purpose of this study, seropositivity on the acutephase specimen required IgM immunoblot positivity, whereas either IgM or IgG positivity was considered indicative of seropositivity on the convalescent-phase specimen. Immunoblots were interpreted in accordance with recommended criteria [4] . 
RESULTS
The study population consisted of 47 untreated adult patients who consented to providing a skin biopsy specimen (diameter, 2 mm) and phlebotomy for culture and serologic testing during the summer of 2000. Culture positivity of skin or blood was present in 31 patients (66.0%), including 7 patients who had a positive blood culture result and a negative culture result of a skin sample. Negative test results in all assays occurred in 3 (6.4%) of the patients, all of whom returned for convalescent-phase serologic testing.
DISCUSSION
Diagnosis of patients with erythema migrans is dependent on recognition of the characteristic appearance of the skin lesion. Laboratory testing is usually not needed, and it is not recommended at this stage of illness. However, studies (such as the present one) are necessary to validate the accuracy of clinical diagnosis, to understand the pathogenesis of infection better, and to evaluate the sensitivity of diagnostic assays. Also, laboratory-authenticated cases of B. burgdorferi infection are important in investigational trials of therapeutic agents and vaccines. We found that culture of a skin biopsy specimen of 2-mm in diameter was positive in 51.1% of patients (table 2), a figure that is comparable to our 1991 study, in which the yield was 57% (21 of 37 subjects). Somewhat greater sensitivity (86%) has been reported by Berger et al. [12] , who cultured a larger skin sample (diameter, 4 mm), and by Steere [13] , for whom the result was 64% among participants in vaccine trial, who may have presented earlier during the course of infection. We have shown elsewhere that the yield of skin culture was inversely correlated with the duration of the erythema migrans lesion [14] . The yield of skin culture in different laboratories may also be affected by the choice of the specific ingredients used in the BSK medium; the particular preparation of BSA, for example, will affect the growth-promoting potential [15] . The yield of our cultures increased to 66% when the results of largevolume blood cultures are included. As reported elsewhere, recovery of B. burgdorferi from blood exceeds 40% if large volumes (∼9 mL) of plasma are cultured [3] .
Quantitative PCR was more sensitive than was culture, and it exceeded the positivity rate obtained by us for nonquantitative PCR in the present study (63.8%), in our earlier study (59%) [2] , and in most studies by other investigators [5] . In an evaluation of known numbers of cultured B. burgdorferi, the quantitative PCR was similarly found to be more sensitive than the nonquantitative PCR used in the current study (data not shown). The enhanced sensitivity of quantitative PCR might be because of improved instrumentation with high-quality optics for detection of PCR product by fluorescence or differences in the choice of the DNA target. The specificity of the assay is unknown, because we did not evaluate it on clinical samples from patients without Lyme disease. Until the specificity of quantitative PCR techniques is determined, the clinical utility of such testing relative to other testing modalities will remain uncertain. However, of the 8 cases with a positive quantitative PCR result but a negative nested PCR result, 5 were culture positive, and 1 additional case that was culture negative was seropositive.
The sensitivity of 2-stage serologic testing of acute-phase samples was 40.4%; for acute-plus convalescent-phase samples, it was 68.1% (71.1%, if patients who did not return for followup testing are excluded). Our results are comparable to [16] or somewhat better than [17] those found in other studies on 2-stage serologic testing of patients with erythema migrans and show that this testing is insensitive for diagnosis at time of presentation and that not all patients will test positive after antibiotic treatment.
Of interest, 3 patients (6.4%) did not test positive by use of any of the assays. Some or all of these patients may not have had B. burgdorferi infection. It is now well recognized that an identical-appearing skin lesion can occur in the absence of B. burgdorferi infection throughout the southern United States [18] . Furthermore, in a recently reported OspA vaccine trial, 15 recipients of placebo developed erythema migrans without laboratory evidence of B. burgdorferi infection [13] . An approximately equal number of cases of erythema migrans without laboratory documentation occurred among the vaccine recipients, which implies a lack of vaccine efficacy for this subgroup of patients. Because the vaccine was highly effective in preventing those cases of erythema migrans for which there was microbiologic evidence of B. burgdorferi infection, lack of efficacy raises the suspicion of an alternative etiology besides B. burgdorferi. It is also conceivable that certain seropositive (but culture-and PCR-negative) patients may not in fact have B. burgdorferi infection as well. Hypothetically, cross-reactivity of antibodies directed to another borrelial agent could account for a portion of such cases. A novel non-B. burgdorferi borrelia has recently been described in Ixodes scapularis ticks [19] .
In summary, advances in PCR technology are associated with increasing sensitivity for detection of B. burgdorferi in skin specimens obtained from untreated adult patients with erythema migrans. Large-volume plasma blood cultures are almost as sensitive as culture of 2-mm skin biopsy samples for recovery of B. burgdorferi and are less invasive. Two-stage serologic testing remains a fairly sensitive diagnostic technique in patients who receive antibiotic therapy at time of presentation, provided that an appropriately timed convalescent-phase serum sample can be obtained. The clinical diagnosis of erythema migrans is highly accurate in an area where B. burgdorferi is endemic if it is made by experienced health care personnel, but some patients with this diagnosis may not have B. burgdorferi infection. 
STUDY GROUP PARTICIPANTS
